Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection.

Honda Y, Inoue J, Shingaki S, Miyazaki K, Abe Y, Sekine E, Iki S, Tsukada N, Suzuki K.

Rinsho Ketsueki. 2014 May;55(5):570-2.

PMID:
24881924
2.

Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.

Ozkurt ZN, Sucak GT, Aki SZ, Yağci M, Erdem O.

Cutan Ocul Toxicol. 2009;28(3):141-3. doi: 10.1080/15569520903046934.

PMID:
19548772
3.

Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Kamimura T, Miyamoto T, Takashima S, Yokota N, Chong Y, Ito Y, Akashi K.

Int J Hematol. 2012 Oct;96(4):525-7. doi: 10.1007/s12185-012-1167-x. Epub 2012 Sep 8. No abstract available.

PMID:
22961216
4.

An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.

Ohgiya D, Tsuchiya T, Suyama T, Watanabe S, Numata H, Tsuboi K, Sasao T.

Acta Haematol. 2015;133(1):29-30. doi: 10.1159/000362587. Epub 2014 Jul 1. No abstract available.

PMID:
24993672
5.

Optimizing bortezomib treatment in patients with relapsed multiple myeloma.

Richardson P.

Clin Adv Hematol Oncol. 2006 May;4(5):4-5; discussion 8; suppl 13. No abstract available.

PMID:
16832859
6.

Subcutaneous bortezomib: a step towards optimised drug use.

Mateos MV.

Lancet Oncol. 2011 May;12(5):410-1. doi: 10.1016/S1470-2045(11)70098-5. Epub 2011 Apr 18. No abstract available.

PMID:
21507716
7.

Bortezomib and bilateral herpes zoster.

di Meo N, Bergamo S, Dondas A, Trevisan G.

Acta Dermatovenerol Alp Pannonica Adriat. 2012;21(1):21-2.

8.

Hyperlipidemia in a myeloma patient after bortezomib treatment.

Gozzetti A, Fabbri A, Defina M, Chitarrelli I, Bocchia M.

Leuk Res. 2010 Sep;34(9):e250. doi: 10.1016/j.leukres.2010.03.025. Epub 2010 Apr 3. No abstract available.

PMID:
20363499
9.

Bortezomib-related colon mucositis in a multiple myeloma patient.

Siniscalchi A, Tendas A, Ales M, Fratoni S, Cupelli L, Dentamaro T, Scaramucci L, Giovannini M, Caravita T, Santeusanio G, Niscola P, de Fabritiis P.

Support Care Cancer. 2009 Apr;17(4):325-7. doi: 10.1007/s00520-008-0573-3. Epub 2009 Jan 27. No abstract available.

PMID:
19172306
10.

[Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].

Titos-Arcos JC, León-Villar J, de Arriba de la Fuente F, Moreno Belmonte MJ, Iranzo Fernández MD.

Farm Hosp. 2012 Jul-Aug;36(4):275-81. Epub 2011 Nov 23. Spanish.

PMID:
22115856
11.

The safety and efficacy of bortezomib in relapsed multiple myeloma.

Jagannath S.

Clin Adv Hematol Oncol. 2006 May;4(5):2-3; discussion 8; suppl 13. No abstract available.

PMID:
16830423
12.

Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.

Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D, Galinier M, Montastruc JL, Pathak A.

Fundam Clin Pharmacol. 2014 Jun;28(3):349-52. doi: 10.1111/fcp.12039. Epub 2013 Jun 19.

PMID:
23781941
13.

Late onset of bortezomib-associated cutaneous reaction following herpes zoster.

Varettoni M, Vassallo C, Borroni G, Mangiacavalli S, Zappasodi P, Rosso R, Lazzarino M, Corso A.

Ann Hematol. 2007 Apr;86(4):301-2. Epub 2006 Nov 25. No abstract available.

PMID:
17131123
14.

[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].

Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K, Komatsu N, Ozawa K.

Rinsho Ketsueki. 2004 Feb;45(2):144-8. Japanese.

PMID:
15045823
15.

Bortezomib increases survival of patients with relapsed multiple myeloma.

[No authors listed]

Health News. 2005 Sep;11(9):9. No abstract available.

PMID:
16211682
16.

Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.

[No authors listed]

Prescrire Int. 2006 Jun;15(83):98-100.

PMID:
16764098
17.

Bortezomib-induced skin eruption.

Sanchez-Politta S, Favet L, Kerl K, Dietrich PY, Piguet V.

Dermatology. 2008;216(2):156-8. doi: 10.1159/000111513. Epub 2008 Jan 23.

18.

Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?

Pitini V, Arrigo C, Altavilla G, Naro C.

Leuk Res. 2007 Jul;31(7):1027-8. Epub 2006 Nov 28. No abstract available.

PMID:
17134751
19.

[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].

Muta T, Nakanishi H, Yasunaga M, Senba S, Murakami H, Kan S, Ueda Y, Fujisaki T.

Gan To Kagaku Ryoho. 2011 Feb;38(2):237-41. Japanese.

PMID:
21368487
20.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361

Supplemental Content

Support Center